Eltrombopag in children with severe aplastic anemia |
Apr 2021 |
Pediatric Blood & Cancer |
Aplastic Anemia, Pediatric |
Eltrombopag for refractory severe aplastic anemia: dosing, duration, long term outcomes and clonal evolution |
Apr 2019 |
Blood |
Aplastic Anemia |
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) |
Jun 2023 |
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) |
Oct 2023 |
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis |
Dec 2023 |
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study |
Jul 2023 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial |
Jun 2023 |
Lancet |
Myelodysplastic Syndromes (MDS) |
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial |
Jul 2023 |
Lancet |
Myelodysplastic Syndromes (MDS) |
Efficacy and Safety of Inhibitors of the Proximal Pathway of the Complement System in Paroxysmal Nocturnal Hemoglobinuria: A Meta-analysis of Randomized Controlled Trials |
Oct 2024 |
American Journal of Therapeutics |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry |
Jan 2019 |
Am J Hematol |
Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH) |